Michael Savona

Dr. Savona is the Head of Hematology, Cellular Therapy and Stem Cell Transplant, the Beverly and George Rawlings Director of Hematologic Malignancies Research, and Professor of Internal Medicine and Cancer Biology at Vanderbilt University. He is a physician scientist specializing in myeloid malignancies, and a leader in development of novel therapies for these patients. He has led development and approval of several novel therapies targeting the proteosome, BCL2 family proteins, PI3 kinase delta, the JAK/STAT pathway, and various epigenetic agents. He studies clonal hematopoiesis (CH) and is interested in the progression of CH to myeloid neoplasia and/or vascular disease.

He has been involved medical research for over 20 years, and has published over 100 manuscripts in major academic journals including: Cancer Discovery, Journal of Clinical Oncology, Nature Medicine, Blood, Cell Stem Cell, Lancet Oncology, Lancet Haematology, JAMA, and Nature Reviews. He is board certified in medical oncology and hematology, an elected fellow of the American College of Physicians, and a Leukemia and Lymphoma Society Clinical Scholar. Dr. Savona obtained his bachelor’s degree in philosophy from Davidson College and medical degree at Wake Forest University School of Medicine in Winston-Salem, North Carolina. He did post graduate clinical and research training at the University of California (Davis / San Francisco), and the University of Michigan.